JP2024522135A - 膵臓癌の治療のためのオートタキシン（ａｔｘ）阻害剤 - Google Patents

膵臓癌の治療のためのオートタキシン（ａｔｘ）阻害剤 Download PDF

Info

Publication number
JP2024522135A
JP2024522135A JP2023574275A JP2023574275A JP2024522135A JP 2024522135 A JP2024522135 A JP 2024522135A JP 2023574275 A JP2023574275 A JP 2023574275A JP 2023574275 A JP2023574275 A JP 2023574275A JP 2024522135 A JP2024522135 A JP 2024522135A
Authority
JP
Japan
Prior art keywords
compound
pancreatic cancer
salt
use according
gemcitabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023574275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522135A5 (enExample
Inventor
ゾーイ・ジョンソン
マルセル・ディーケン
マイケル・ラーン
ダヴィデ・メリシ
Original Assignee
アイオンクチュラ・ベー・フェー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイオンクチュラ・ベー・フェー filed Critical アイオンクチュラ・ベー・フェー
Publication of JP2024522135A publication Critical patent/JP2024522135A/ja
Publication of JP2024522135A5 publication Critical patent/JP2024522135A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023574275A 2021-06-09 2022-06-08 膵臓癌の治療のためのオートタキシン（ａｔｘ）阻害剤 Pending JP2024522135A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2108245.8 2021-06-09
GBGB2108245.8A GB202108245D0 (en) 2021-06-09 2021-06-09 Methods of treatment
PCT/EP2022/065562 WO2022258693A1 (en) 2021-06-09 2022-06-08 Autotaxin (atx) inhibitor for the treatment of pancreatic cancer

Publications (2)

Publication Number Publication Date
JP2024522135A true JP2024522135A (ja) 2024-06-11
JP2024522135A5 JP2024522135A5 (enExample) 2025-06-16

Family

ID=76838834

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023574275A Pending JP2024522135A (ja) 2021-06-09 2022-06-08 膵臓癌の治療のためのオートタキシン（ａｔｘ）阻害剤

Country Status (9)

Country Link
US (1) US20250057820A1 (enExample)
EP (1) EP4351563A1 (enExample)
JP (1) JP2024522135A (enExample)
CN (1) CN117295496A (enExample)
AU (1) AU2022290378B2 (enExample)
CA (1) CA3218103A1 (enExample)
GB (1) GB202108245D0 (enExample)
MX (1) MX2023014637A (enExample)
WO (1) WO2022258693A1 (enExample)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508498A (ja) * 2015-02-06 2018-03-29 キャンサー・リサーチ・テクノロジー・リミテッド オートタキシン阻害化合物
JP2024511836A (ja) * 2021-03-29 2024-03-15 アイオンクチュラ・ソシエテ・アノニム 膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9850203B2 (en) * 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508498A (ja) * 2015-02-06 2018-03-29 キャンサー・リサーチ・テクノロジー・リミテッド オートタキシン阻害化合物
JP2024511836A (ja) * 2021-03-29 2024-03-15 アイオンクチュラ・ソシエテ・アノニム 膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Inhibition of the autotaxin/lysophosphatidic acid (ATX/LPA) pathway reduces pancreatic cancer tumor", ANNALS OF SURGICAL ONCOLOGY, vol. Vol.25,No.1,Supplement1, JPN6025051106, 2018, pages 117 - 118, ISSN: 0005829087 *
CANCER SCIENCE, vol. 112, JPN6025051107, February 2021 (2021-02-01), pages 668 - 678, ISSN: 0005829086 *
JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, vol. 38, no. 4, JPN6025051104, 2018, pages 367 - 371, ISSN: 0005829088 *
TUMOR BIOLOGY, vol. 39, no. 3, JPN6025030908, March 2017 (2017-03-01), pages 101042831769454, ISSN: 0005829084 *
膵癌診療ガイドライン ２０１９年版 一般社団法人日本膵臓学会, JPN6025030909, 2019, pages 81 - 83, ISSN: 0005829085 *

Also Published As

Publication number Publication date
AU2022290378A1 (en) 2024-01-04
AU2022290378B2 (en) 2026-06-11
WO2022258693A1 (en) 2022-12-15
EP4351563A1 (en) 2024-04-17
MX2023014637A (es) 2024-01-31
GB202108245D0 (en) 2021-07-21
CA3218103A1 (en) 2022-12-15
US20250057820A1 (en) 2025-02-20
CN117295496A (zh) 2023-12-26

Similar Documents

Publication Publication Date Title
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
AU2012321110B2 (en) Combination treatment
US11491168B2 (en) Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
EP4110326B1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
JP6911048B2 (ja) がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法
JP2013543879A (ja) 急性骨髄性白血病を治療するための単独またはシタラビンとの組合せにおけるボラセルチブ
WO2015015013A1 (en) Combinations of a btk inhibitor and fluorouracil for treating cancers
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
CN103533940A (zh) 治疗晚期实体瘤的方法
CN114159446A (zh) 组织蛋白酶c抑制剂在治疗肿瘤转移中的应用
WO2023092943A1 (zh) 盐酸决奈达隆联合5-氟尿嘧啶在制备抗肿瘤药物中的应用
JP2025509278A (ja) 小細胞肺癌を治療する方法
US20240216385A1 (en) A pi3k-delta inhibitor for the treatment of pancreatic cancer
JP2021063014A (ja) 白血病治療薬
US20250057820A1 (en) Autotaxin (atx) inhibitor for the treatment of pancreatic cancer
EP2663318B1 (en) Pharmaceutical composition for treating cancer
TW201907916A (zh) 基於癌細胞之代謝特異性之新穎抗惡性腫瘤劑
KR20240164549A (ko) 암 치료를 위한 metap2 억제제를 포함하는 조합
EP1757283B1 (en) Antitumor effect fortifier, antitumor agent and method of therapy for cancer
RU2519199C2 (ru) Противоопухолевый агент, набор и способ лечения рака
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
WO2024246824A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
HK40110657A (en) Cdk4 inhibitor for the treatment of cancer
WO2025056747A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
CN116997340A (zh) 用于治疗胰腺癌的PI3K-δ抑制剂

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250606

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250606

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260731